ES2196305T3 - Composiciones que contienen moleculas inmunogenas y factor de estimulacion de colonias de granulocitos magrofagos como adyuvante. - Google Patents

Composiciones que contienen moleculas inmunogenas y factor de estimulacion de colonias de granulocitos magrofagos como adyuvante.

Info

Publication number
ES2196305T3
ES2196305T3 ES97904876T ES97904876T ES2196305T3 ES 2196305 T3 ES2196305 T3 ES 2196305T3 ES 97904876 T ES97904876 T ES 97904876T ES 97904876 T ES97904876 T ES 97904876T ES 2196305 T3 ES2196305 T3 ES 2196305T3
Authority
ES
Spain
Prior art keywords
magrophagic
granulocit
colonies
adjuvant
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97904876T
Other languages
English (en)
Inventor
Elke Jager
Alexander Knuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2196305T3 publication Critical patent/ES2196305T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE HA DESCUBIERTO QUE EL FACTOR DE ESTIMULACION DE COLONIA DE GRANULOCITA-MACROFAGO ("GM-CSF") ACTUA COMO UN ADYUVANTE CUANDO SE ADMINISTRA A SUJETOS. SE PRESENTAN COMPOSICIONES DE GM-CSF Y COMPOSICIONES INMUNOGENAS, COMO SUELE HACERSE EN EL CASO DE GMCSF DE MANERA INDIVIDUAL Y EN ESTAS COMPOSICIONES.
ES97904876T 1996-02-09 1997-01-28 Composiciones que contienen moleculas inmunogenas y factor de estimulacion de colonias de granulocitos magrofagos como adyuvante. Expired - Lifetime ES2196305T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/598,909 US6096313A (en) 1996-02-09 1996-02-09 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Publications (1)

Publication Number Publication Date
ES2196305T3 true ES2196305T3 (es) 2003-12-16

Family

ID=24397438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97904876T Expired - Lifetime ES2196305T3 (es) 1996-02-09 1997-01-28 Composiciones que contienen moleculas inmunogenas y factor de estimulacion de colonias de granulocitos magrofagos como adyuvante.

Country Status (12)

Country Link
US (1) US6096313A (es)
EP (1) EP0932411B1 (es)
JP (1) JP2000506518A (es)
AT (1) ATE243525T1 (es)
AU (1) AU723147B2 (es)
CA (1) CA2244867C (es)
DE (1) DE69723092T2 (es)
DK (1) DK0932411T3 (es)
ES (1) ES2196305T3 (es)
PT (1) PT932411E (es)
WO (1) WO1997028816A1 (es)
ZA (1) ZA97858B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2000069456A2 (en) * 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
TW581709B (en) 1999-10-22 2004-04-01 Asahi Kasei Corp Heat-resistant microporous film
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP1309373A2 (en) * 2000-08-11 2003-05-14 Favrille, Inc. Method and composition for altering a t cell mediated pathology
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2502577C (en) * 2002-10-18 2008-11-04 Asahi Kasei Pharma Corporation Hydrophilic microporous membrane
ES2661082T3 (es) 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
PT1691824E (pt) 2003-11-19 2009-05-28 Merck Patent Gmbh Proteínas pertencentes à família bcl-2 e seus fragmentos e sua utilização em doentes de cancro
EP1720565A1 (en) * 2004-03-04 2006-11-15 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP2008528643A (ja) 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB2432722A (en) * 2005-11-25 2007-05-30 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432723B (en) * 2005-11-25 2010-12-08 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432721B (en) * 2005-11-25 2011-06-22 Seiko Epson Corp Electrochemical cell structure and method of fabrication
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
BRPI0814140A2 (pt) * 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
NZ588757A (en) 2008-04-17 2012-05-25 Herlev Hospital Indoleamine 2, 3-dioxygenase based immunotherapy
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2546358A1 (en) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Methods and reagents for efficient control of HIV progression
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
EP4079319A1 (en) 2011-10-17 2022-10-26 IO Biotech ApS Pd-l1 based immunotherapy
WO2013060328A1 (en) 2011-10-26 2013-05-02 Herlev Hospital Ikb based immunotherapy
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
EP2617434A1 (en) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
EP2703482A1 (en) 2012-09-04 2014-03-05 Laboratorios Del. Dr. Esteve, S.A. VSV-HIV viral particles lacking reverse transcriptase functionality and therapeutic applications thereof
PL2886126T3 (pl) 2013-12-23 2017-11-30 Exchange Imaging Technologies Gmbh Nanocząstka sprzężona z peptydami wiążącymi CD44
LT3193917T (lt) 2014-09-17 2021-11-25 Io Biotech Aps Vakcinų kompozicijos, apimančios triptofan-2,3-dioksigenazę arba jos fragmentus
EP3349785A1 (en) 2015-09-16 2018-07-25 Herlev Hospital Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
EP3147364A1 (en) 2015-09-28 2017-03-29 Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) Antiviral agents comprising an oligonucleotide-lipid conjugate forming g-quadruplex
WO2017211371A2 (en) 2016-06-10 2017-12-14 Herlev Hospital Calr and jak2 vaccine compositions
EP3275462A1 (en) 2016-07-27 2018-01-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Virus-like particles with high-density coating for the production of neutralizing antibodies
AU2020279988A1 (en) 2019-05-22 2021-12-23 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
JP2001517206A (ja) * 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法

Also Published As

Publication number Publication date
JP2000506518A (ja) 2000-05-30
DE69723092T2 (de) 2003-12-18
DE69723092D1 (de) 2003-07-31
ATE243525T1 (de) 2003-07-15
EP0932411A1 (en) 1999-08-04
AU1755297A (en) 1997-08-28
CA2244867C (en) 2003-09-09
ZA97858B (en) 1997-08-04
WO1997028816A1 (en) 1997-08-14
US6096313A (en) 2000-08-01
CA2244867A1 (en) 1997-08-14
PT932411E (pt) 2003-11-28
EP0932411B1 (en) 2003-06-25
DK0932411T3 (da) 2003-08-18
AU723147B2 (en) 2000-08-17
EP0932411A4 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
ES2196305T3 (es) Composiciones que contienen moleculas inmunogenas y factor de estimulacion de colonias de granulocitos magrofagos como adyuvante.
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
DE3683528D1 (de) Tetrapyrrol-therapiemittel.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
CY1116145T1 (el) S-φθορομεθυλεστερας 6.αλφα.,9.αλφα-διφθορο-17.αλφα.-'(2-φουρανυλκαρβοξυλ) οξυ]-11.βητα.-υδροξυ-16.αλφα.-μεθυλ-3-οξο-ανδροστ-1,4-διεν-17-καρβοθειοτικου οξεος ως αντιφλεγμονωδης παραγοντας
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2195970T3 (es) L-ribavirina y usos de la misma.
TR199900239T2 (es)
ES2033774T3 (es) Derivados antiviricos fosfonometoxialquilenicos de purina y pirimidina.
ES2184794T3 (es) Profarmacos de morfolina como antagonistas de receptores de taquicininas.
AR001440A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
ES2052556T3 (es) Fungicidas.
BR0111639A (pt) Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
PA8432901A1 (es) Compuestos de piridilpirrol
ES2107284T3 (es) Nuevas n-piridil-carboxamidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ATE35416T1 (de) Derivate des glycerophosphocholins und glycerophosphoethanolamins, ihre herstellung und verwendung.
FI972054A (fi) Immunogeenisiä koostumuksia
ES2096973T3 (es) Fosfazenos que contienen radicales organicos de silicio, proceso para su preparacion, y su empleo.
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
MX9102101A (es) Composiciones que contienen psyllium. composiciones que contienen psyllium.
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
ES2128794T3 (es) Composiciones de poliuretano con reactividad estable.
JPS57128666A (en) Peptides, manufacture and use as medicine
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.